Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,138,804
-
Total 13F shares
-
2,777,239
-
Share change
-
+326,109
-
Total reported value
-
$3,612,208
-
Put/Call ratio
-
0%
-
Price per share
-
$1.30
-
Number of holders
-
26
-
Value change
-
+$302,490
-
Number of buys
-
10
-
Number of sells
-
9
Institutional Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q3 2021
As of 30 Sep 2021,
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,777,239 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, COMMONWEALTH EQUITY SERVICES, LLC, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, SUSQUEHANNA INTERNATIONAL GROUP, LLP, FRANKLIN RESOURCES INC, HighMark Wealth Management LLC, and GSA CAPITAL PARTNERS LLP.
This page lists
26
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.